Business

The one-sentence verdict

Synchrony is a genuinely high-return business — a private-label card lender that earns a ~3% return on assets and a roughly 25% return on tangible common equity through the cycle [3] — that the market prices like a low-quality cyclical, at about 8x earnings and 1.8x book value. The gap is the whole investment case. You are not buying a wide-moat compounder; you are buying a concentrated, narrow-moat, high-yield/high-loss spread lender whose management converts a 20%-plus equity return into per-share value almost entirely through capital return — having retired more than half its shares since 2014. Underwrite it on capital generation and the credit cycle, not on growth.

Source: FY2025 Annual Report (Form 10-K), Other Financial and Statistical Data [1]; Q4 FY2025 earnings call, full-year results [2]; P/E and P/B derived from reported earnings and common equity at a $75.26 share price.

1. Why the returns are structurally high — and how durable they are

A 25% return on tangible equity is not an accident of one good year; it is the arithmetic of three structural features stacked on top of each other. Read it as a bridge from a fat margin to a fat return.

Source: FY2025 Annual Report (Form 10-K), Average Balance Sheet [5] and Other Financial and Statistical Data [1].

The piece an investor most often underrates is the efficiency ratio of 34.3% [1] — meaning it costs Synchrony roughly 34 cents of operating expense to produce a dollar of net revenue. A typical large bank runs 55–65%. Synchrony gets there because it has no branch network — it gathers $81.1 billion of deposits, 84% of total funding, entirely online [6] — runs a single product platform, and lets its retail partners carry the cost of customer acquisition at the point of sale. Low cost-to-serve is the quiet third leg of the return, alongside the high yield and the cheap funding.

The high yield (22.34% on card receivables) is not free money; it is paid for in 5.65% net charge-offs [5] [1]. The durability question therefore reduces to one thing: can management hold losses inside its target band while keeping the spread? The track record says yes — management notes that since exiting the pandemic in 2021 it has grown receivables ~7% annually while delivering an average ~3% ROA and ~25% return on tangible common equity across a full credit cycle [3]. That is the single most important fact about business quality on this page: the high returns persisted through a charge-off cycle that ran from 2.9% up to 6.3% and back down.

2. The capital-return engine — this is the actual investment case

A 20%-plus ROE business that grows its balance sheet only mid-single-digits generates far more capital than it can reinvest. What it does with the surplus is the thesis. Synchrony's answer has been relentless: shrink the share count.

Source: derived from reported period-end share counts; FY2025 repurchase of 43.7 million shares for $2.9 billion per the FY2025 Annual Report (Form 10-K) [9].

Share count has fallen from 831.5 million in 2016 to 373.9 million at the end of 2025 — a 55% reduction. In FY2025 alone Synchrony repurchased 43.7 million shares for $2.9 billion and paid $427 million in dividends, returning $3.3 billion to shareholders [9] [7]. That single-year payout equals roughly 12% of the current ~$28 billion market capitalization. And the pace is accelerating: in the first quarter of 2026 the Board approved a new $6.5 billion repurchase program with no expiration date — about 23% of the entire market cap — and management said it is "well positioned to return excess capital in an aggressive but prudent way" [4].

Source: derived from reported financing cash flows; FY2025 figures per FY2025 Annual Report (Form 10-K), Business Trends and Conditions [7] and Equity note [9].

Across 2016–2025 Synchrony has returned roughly $24 billion — buybacks plus dividends — against today's ~$28 billion equity value. Two things make this engine credible rather than financial-engineering hope. First, it is funded by real cash, not leverage: the business produced $9.9 billion of operating cash flow in 2025, and the capital ratios stayed fortress-grade — a Basel III CET1 ratio of 12.6% and total capital ratio of 15.8% at year-end, well above regulatory minimums [8]. Second, buying back stock below ~1.8x book at a ~20% ROE is accretive math — each repurchased share permanently lifts per-share book value and earnings for those who stay.

The compounding shows up in book value per share

Source: derived from reported common equity (total equity less $1,222M preferred) and period-end shares; preferred and goodwill/intangible balances per FY2025 Annual Report (Form 10-K) [9].

Book value per common share has compounded from roughly $22.70 in 2021 to ~$41.57 in 2025 even as the company returned more than its annual earnings to shareholders — the signature of a business out-earning its growth needs. Management reports the cleaner version of the same fact: tangible book value per share grew 9% in 2025 and another 8% year-on-year in Q1 2026, with quarterly ROTCE of 24.5% [2] [23]. Management frames the model explicitly as designed "to generate double-digit earnings per share growth on average over time and through cycles" [3] — and with mid-single-digit loan growth, the rest of that double-digit comes from the shrinking share count.

3. The moat — narrow and concentrated, with one genuinely differentiated asset

Be honest about what protects these returns. The private-label card business is fundamentally a distribution business won on competitive RFPs, and the partner captures much of the upside through the retailer share arrangement. That is not a wide moat. But four mechanisms create real, if narrow, defensibility — graded below by how durable each actually is.

Source: FY2025 Annual Report (Form 10-K) — Health and Wellness/CareCredit [11]; partner tenure and concentration [10]; PRISM/underwriting [12]; funding [6].

The single best asset is CareCredit. Health and Wellness finances elective medical, dental, and veterinary care across a provider network exceeding 290,000 locations [11]. Unlike a retail card program tied to one merchant, CareCredit is a genuine two-sided network — providers want it because it gets patients to say yes to care, patients carry it across providers — which is why management keeps singling out Health and Wellness for accelerated investment. It has low single-partner concentration and a structural demographic tailwind. This is the closest thing Synchrony has to a Visa/Amex-style network effect, and it deserves a higher multiple than the rest of the book.

The biggest risk to the moat is the mirror image of its strength: concentration. Synchrony's five largest programs — Amazon, Lowe's, PayPal, Sam's Club and TJX — generated 54% of total interest and fees on loans in 2025 [10]. A single lost renewal can move the whole company — exactly what happened when Walmart left years ago (and, notably, what Synchrony just reversed by winning the Walmart/OnePay program). The mitigant is contract length and staggering: top-five relationships average over 14 years (46 for Lowe's), and 22 of the 25 largest programs run to 2028 or beyond [10]. Net verdict: a narrow moat — real switching costs and data scale, one strong network in CareCredit, but offset by RFP competition, RSA give-backs, and dangerous program concentration.

4. Competitive reality — caught between a premium franchise and a regulatory-arbitrage threat

Synchrony fights on two fronts: for partner programs against other card banks, and for the deposits that fund them. Its named rivals for partners are "American Express, Bread Financial, Capital One/Discover, JPMorgan Chase, Citibank, TD Bank and Wells Fargo" [15]; the newer threat is non-bank "pay-over-time" players such as Affirm, Afterpay and Klarna that "do not face the same restrictions, such as capital requirements," as banks [16]. The peer set below is drawn from companies Synchrony names in its own 10-K, with each business model confirmed from the peer's own filing.

Source: business models confirmed from each peer's FY2025 10-K — Bread Financial [18], Capital One [19] [20], American Express [21], Affirm [22]; valuation multiples and ROE derived from staged company snapshots and reported financials.

Source: ROE and P/B derived from each company's reported FY2025 financials and staged market-cap snapshots; business-model peer set per Synchrony's FY2025 10-K Competition section [15]. (Affirm excluded from chart — near-zero ROE with an 8x book multiple distorts the scale.)

Three reads from the comparison:

• The true pure-play, Bread Financial, validates the cheapness — and the discount Synchrony has earned. Bread runs the identical partner-funded private-label model [18] yet earns a lower ~16% ROE at a similar ~8x P/E and a lower 1.2x book. Synchrony is the higher-quality version of the same business — larger, more efficient, better-funded — and trades only modestly above it. That is the core mispricing.
• American Express is the franchise Synchrony can never be — and the market knows it. Amex's integrated spend-centric network earns a 32% ROE and commands ~6.9x book [21]. Synchrony's nearly-as-high ROE earns barely a quarter of that multiple because its returns are seen as cyclical credit risk, not annuity spend. The valuation gap is a judgment on moat quality, not on returns.
• Capital One/Discover is the structural threat with cheaper, more diversified funding — now the largest US issuer and enlarged by the May 2025 Discover acquisition, which hands it a payment network Synchrony lacks [19] [20]. (Its FY2025 P/E is not meaningful — earnings were depressed by Discover-related CECL reserve building.) On the fintech flank, Affirm explicitly names Synchrony as a competing card-issuing bank [22], but at near-zero profit and 8x book it is priced on hope, not returns — a share-shift risk at the checkout, not an economic peer.

5. How to value it — the lens that fits a spread lender

For a high-ROE, capital-return-driven lender, the right framework is price-to-book read against ROE, cross-checked by through-cycle earnings power and the capital-return yield — not a growth multiple.

Source: 2026 EPS guidance and capital-return framing from Q1 FY2026 earnings call [4]; through-cycle return profile from Q4 FY2025 call [3]; ROE/book per FY2025 10-K [1].

The arithmetic of a spread lender is unforgiving and clarifying: a bank that sustainably earns ROE well above its cost of equity should trade at a premium to book equal to roughly (ROE − g) / (COE − g). Even on conservative inputs — a normalized 18% ROE, a 10% cost of equity, 4% growth — that formula implies well over 2x book. Synchrony trades at ~1.8x book and ~8x earnings [1]. The market is therefore underwriting either (a) a much lower normalized ROE than realized, (b) a sharply higher cost of equity for credit-cycle risk, or (c) a permanent terminal decline from BNPL/regulation. The bull case is that none of those is as bad as priced and the buyback compounds book value regardless; the bear case is that the credit cycle and partner concentration make those discounts rational.

The cleanest way to hold it: this is a "return-of-capital compounder," not a growth stock. With 2026 EPS guided to $9.10–$9.50 [4], the stock at ~$75 sits around 8x forward earnings while the company hands back close to its entire profit each year and shrinks the count. You do not need multiple expansion to do well — you need the credit cycle to behave and the top partners to renew. If the multiple re-rates toward the quality of the returns, that is upside, not the base case.

6. The watchlist — what would change the underwrite

The returns above are levered to a small number of variables. These are the dials an investor should track, roughly in order of impact on the thesis.

Source: charge-off target and partner concentration per FY2025 10-K, Business Trends and Conditions [7] and Partner Agreements [10]; buyback program and capital framing per Q1 FY2026 call [4].

Bottom line. Synchrony is a high-quality lender wearing a low-quality multiple. The business genuinely earns ~25% on tangible equity through the cycle, runs the most efficient cost structure among card issuers, and converts its surplus capital into per-share value with unusual discipline — it has retired 55% of its shares and now carries the original franchise that began life as a GE division and IPO'd in 2014 as "the largest provider of private label credit cards in the United States" [17]. What it does not have is a wide moat or low-cyclicality earnings, which is why it is cheap. Underwrite the credit cycle and the buyback, respect the partner concentration, and the rest takes care of itself.